Skip to content

Subtype-Specific Treatment of Sudden deafness with Integrated Chinese and Western Medicine: A Real-World Study

Subtype-Specific Treatment of Sudden deafness with Integrated Chinese and Western Medicine: A Real-World Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000557
Enrollment
Unknown
Registered
2026-03-18
Start date
2026-01-09
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden deafness

Interventions

Western medicine treatment group:Conventional Western medical drug treatment
Combined treatment of Western medicine and traditional Chinese medicine group:Conventional Western medical treatment combined with TCM syndrome differentiation-based herbal medicine treatment
Combined treatment of Western medicine, TCM and acupuncture group:Conventional Western medical treatment combined with TCM syndrome differentiation-based herbal medicine treatment and TCM acupuncture

Sponsors

Shandong Second Provincial General Hospital(Shandong ENT Hospital, Shandong Institute of Otolaryngology)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1: (1) Meets the diagnosis of unilateral idiopathic sudden sensorineural hearing loss 2: (2) Disease duration = 30 days 3: (3) Age = 18 years old 4: (4) Voluntarily consents to and is able to cooperate with the completion of the study.

Exclusion criteria

Exclusion criteria: 1:   (1) Patients with hemorrhagic diseases 2:   (2) Patients allergic to the study drugs or with an allergic diathesis 3:   (3) Patients with severe liver or kidney diseases 4:   (4) Patients with mental illnesses or Alzheimer's disease who are unable to cooperate with the completion of the clinical study 5:   (5) Pregnant women, lactating women, and athletes 6:   (6) Patients concurrently participating in other clinical studies 7:   (7) Patients who have previously received a sufficient dose of oral or intravenous hormones (prednisone 1mg/kg per day for 5 consecutive days, or methylprednisolone 40mg/dexamethasone 10mg per day for 5 consecutive days, or equivalent doses of other types of hormones converted to the aforementioned benchmark hormones) 8:   (8) Patients deemed unsuitable for inclusion by the researchers (excluding those with a history of middle ear diseases, previous contralateral hearing loss, poor previous binaural hearing levels, inner ear malformations, cerebellopontine angle space-occupying lesions, etc.).

Design outcomes

Primary

MeasureTime frame
Pure Tone Audiometry Threshold Average(PTA);

Secondary

MeasureTime frame
Word Recognition Score;Tinnitus Handicap Inventory (THI);Visual Analog Scale (VAS);Dizziness Handicap Inventory (DHI); Vertigo Symptom Scale-Short Form (VSS-sf);Visual Analog Scale (VAS) for Ear Fullness/Pressure Sensation;Visual Analog Scale (VAS) for Periauricular Numbness;Insomnia Severity Index (ISI) ; Pittsburgh Sleep Quality Index (PSQI);Balanced Constitution and Unbalanced Constitution Determination Criteria Table;Traditional Chinese Medicine (TCM) Constitution Classification and Determination Table.;

Countries

China

Contacts

Public ContactMingMing Wang

Shandong Second Provincial General Hospital(Shandong ENT Hospital, Shandong Institute of Otolaryngology)

wmmship@126.com15168887583

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026